It is important to analyze a pharmaceutical company’s entire pipeline, not just its drugs in late-stage trials, says John LaMattina, a former Pfizer R&D president and senior partner at PureTech Ventures. The information will indicate a company's therapeutic priority areas and strategies. He says some drug companies are very transparent with information about their early-stage assets.

Full Story:

Related Summaries